Barclays
CLYM

Barclays’s Climb Bio CLYM Stock Holding History

Barclays’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335K Sell
48,936
-12,917
-21% -$74.5K ﹤0.01% 3412
2025
Q4 		$247K Buy
61,853
+37,100
+150% +$89.1K ﹤0.01% 4209
2025
Q3 		$49.8K Sell
24,753
-4,624
-16% -$8.59K ﹤0.01% 4771
2025
Q2 		$36.4K Sell
29,377
-29,353
-50% -$36.5K ﹤0.01% 4752
2025
Q1 		$71.7K Buy
58,730
+8,926
+18% +$14.5K ﹤0.01% 4509
2024
Q4 		$89.6K Buy
49,804
+10,945
+28% +$39.6K ﹤0.01% 4618
2024
Q3 		$198K Buy
38,859
+36,316
+1,428% +$257K ﹤0.01% 4301
2024
Q2 		$18.1K Buy
+2,543
New +$16.9K ﹤0.01% 4451
2022
Q2 		– Sell
-2,850
Closed -$24K – 5317
2022
Q1 		$24K Buy
+2,850
New +$26.6K ﹤0.01% 4396

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $408M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return